semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Right or Left Breast Mammary Reconstruction Malignant Neoplasm Reconstruction by Tattoo of Areola of Female Breast technology areola tattoo realized as part of 1 breast mammary reconstruction following an operated breast cancer  Two breasts operated patient surgical reconstruction
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women (age 18-100) undergoing preoperative evaluation at the University of Kansas Cancer Center (KUCC) for a new diagnosis of breast cancer Patients with a diagnosis of breast cancer by either core needle biopsy or excisional biopsy Bilateral mammography and hand-held ultrasound (if clinically indicated) performed prior to the MRI and ABUS If a breast MRI is advised and there is no contraindication to MRI, a breast MRI and ABUS will performed at KUCC (Study Arm 1) If a breast MRI is not performed, an ABUS exam without MRI will be performed (Study Arm 2) The MRI and ABUS exam must be obtained within 2 weeks of each other  Males Pregnant women Lactating women Patients < 18 and > 100 years of age Patients with breast implants
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients attending the breast clinic undergoing mammography and/or ultrasound who can give written informed consent The investigators aim to recruit 150 patients likely to have breast cancer clinically and 150 patients who have normal breasts/benign abnormalities  Patients unable to give written informed consent Patients not having appropriate imaging (mammography +/ ultrasound)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Node-positive Breast Cancer Breast Adenocarcinoma Invasive Breast Carcinoma Lobular Breast Carcinoma In Situ Karnofsky performance status of 70-100% Histologic documentation of invasive adenocarcinoma of the breast One of the breast disease stages listed below Note: In the definitions below, definitive surgery is defined as the final surgery performed to obtain clear surgical margins Neoadjuvant chemotherapy was not administered ** If neoadjuvant chemotherapy was NOT administered, pathologic staging must be T1-3, N1-2a following definitive surgery Neoadjuvant chemotherapy was administered If prior to initiation of neoadjuvant chemotherapy clinical staging was T1-3, N0, pathologic staging must be T1-3, N1-2a following definitive surgery If prior to initiation of neoadjuvant chemotherapy clinical staging was T1-3, N1, pathologic staging must be T0-3, N0-2a following definitive surgery If prior to initiation of neoadjuvant chemotherapy there was cytologic or pathologic confirmation of axillary nodal involvement (per any of the listed below), pathologic staging must be T0-3, N0-2a following definitive surgery Positive fine-needle aspiration (FNA) (ie, demonstrating malignant cells)  Known definitive clinical or radiologic evidence of metastatic disease T4 tumors including inflammatory breast cancer Clinical nodal staging of N2 or N3 disease Pathologic nodal staging of N2b, N2c, or N3 disease Microscopic positive margins after definitive surgery * Note: Patients with microscopically focally positive margins following lumpectomy or mastectomy are not excluded if re-excision is not technically feasible and/or there is no benefit to further surgery based on the extent and location of the positive margin Any history, not including the index cancer, of ipsilateral or contralateral invasive breast cancer or ipsilateral or contralateral DCIS treated with radiation therapy (RT) * Note: Patients with synchronous or previous ipsilateral LCIS are eligible Any radiation therapy (RT) for the currently diagnosed breast cancer prior to study enrollment History of ipsilateral or contralateral breast or thoracic RT for any condition History of ipsilateral or contralateral axillary surgery for any condition History of lymphedema involving the ipsilateral or contralateral arm at present or at any time in the past
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 45.0-999.0,  Ductal Breast Carcinoma In Situ Estrogen Receptor Positive Invasive Breast Carcinoma Progesterone Receptor Positive Stage IA Breast Cancer Stage IB Breast Cancer Stage IIA Breast Cancer Must sign informed consent Surgical treatment of the breast must have been lumpectomy; the margins of the resected specimen must be histologically free of tumor (negative surgical margins per National Surgical Adjuvant Breast and Bowel Project [NSABP] criteria) On histologic examination, the tumor must be ductal carcinoma in situ (DCIS) and/or invasive breast carcinoma For patients with invasive breast cancer, an axillary staging procedure must be performed (either sentinel node biopsy [SNB] alone or axillary dissection [with a minimum of six axillary nodes removed], and the axillary node[s] must be pathologically negative); patients over 70 with estrogen receptor positive (ER+) tumors no greater than 2 cm do not require axillary evaluation, but MUST be clinically node negative on examination and all available imaging (clinical N0) The T stage must be Tis, T1, or T2; if T2, the tumor must be =< 3.0 cm in maximum diameter Estrogen receptor positive tumor and/or progesterone receptor positive tumor  Pregnant or breast-feeding Active collagen-vascular disease Paget's disease of the breast Prior history of DCIS or invasive breast cancer Prior breast or thoracic radiation therapy (RT) for any condition Multicentric carcinoma (DCIS or invasive) Synchronous bilateral invasive or non-invasive breast cancer Surgical margins that cannot be microscopically assessed or that are positive Positive axillary node(s) T stage of T2 with the tumor > 3 cm in maximum diameter or a T stage >= 3
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Intrahepatic Cholangiocarcinoma Male or female patients > 18 years and <=70 years of age Diagnosis of intrahepatic cholangiocarcinoma ( through imaging, serology, intraoperative frozen, etc.) No lymph node metastasis preoperatively or intraoperatively Tumors can be completely resected of liver function: Child A-B level, serum bilirubin ≤ 1.5 times the upper limit of normal value, alanine aminotransferase and aspartate aminotransferase ≤ 2 times the upper limit of normal value Patients who can understand this trial and have signed information consent. Criteria:Lymph node metastasis preoperatively Tumors can not be resected  Patients with apparent cardiac, pulmonary, cerebral and renal dysfunction, which may affect the treatment of Intrahepatic cholangiocarcinoma Patients with a medical history of other malignant tumors Subjects participating in other clinical trials
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Pain, Postoperative Postoperative Nausea and Vomiting Primary breast cancer without known extension beyond the breast and axillary nodes (i.e. believed to be Tumor Stage 1-3, Nodes 0-2) Scheduled for unilateral or bilateral mastectomy with or without implant (isolated "lumpectomy" will not qualify) Isolated "lumpectomy" with axillary node dissection (anticipated removal of at least five nodes) Written informed consent, including willingness to be randomized to opioids or regional analgesia Dutch speaking  Previous surgery for breast cancer (except diagnostic biopsies) Inflammatory breast cancer Scheduled free flap reconstruction ASA Physical Status ≥ 4 Any contraindication to locoregional analgesia (including coagulopathy, abnormal anatomy) Any contraindication to midazolam, propofol, sevoflurane, sufentanyl, tramadol or piritramide Other cancer not believed by the attending surgeon to be in long-term remission Systemic disease believed by the attending surgeon to present ≥ 25% two-year mortality Obesity defined as BMI ≥ 30 kg/m2 Chronic use of pain medication (started > 3 months ago)
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Neoplasms Women aged ≥18 years and < 70 years with life expectancy > 12 months 2. Have finished radical operation, pathologically verified no lymph node involvement 3. Operation specimens are available for ER, progesterone receptor (PR) and Her2 detection, patients should be with ER positive, Her2 negative tumor. 4. Adequate bone marrow function 5. Adequate liver and renal function 6. Has Eastern Cooperative Oncology Group (ECOG0 Performance Score 0-1; 7. Women with potential child-bearing must have a negative pregnancy test (urine or serum) within 7 days of drug administration and agree to use an acceptable method of birth control to avoid pregnancy for the duration of the study; 8. Written informed consent according to the local ethics committee requirements  Prior systemic or loco-regional treatment of breast cancer, including chemotherapy; 2. Metastatic breast cancer; 3. With a history of malignant tumor except uterine cervix cancer in situ or skin basal cell carcinoma; 4. Patients with medical conditions that indicate intolerant to adjuvant chemotherapy and related treatment, including uncontrolled pulmonary disease, diabetes mellitus, severe infection, active peptic ulcer, coagulation disorder, connective tissue disease or myelo-suppressive disease; 5. Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive; 6. History of congestive heart failure, uncontrolled or symptomatic angina pectoris, arrhythmia or myocardial infarction; poorly controlled hypertension; 7. Has peripheral neuropathy ≥ grade 1; 8. Patient is pregnant or breast feeding; 9. Known severe hypersensitivity to any drugs in this study; 10. Treatment with any investigational drugs within 30 days before the beginning of study treatment
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 9.0-999.0,  Hyperhidrosis Completed Day 28 of either the DRM04-HH04 or DRM04-HH05 study with at least 80% treatment compliance Male or females  Subject has a clinically significant abnormality on physical exam, vital signs or ECG at the Week 4 visit of DRM04-HH04 or DRM04-HH05 study that would make further treatment with glycopyrronium contraindicated Male with a history of urinary retention requiring catheterization due to prostatic hypertrophy or severe obstructive symptoms of prostatic hypertrophy Any other condition which, in the judgement of the Investigator, would put the subject at unacceptable risk for participation in the study
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer women breast cancer diagnosis all races will be included  men those with no breast cancer (ductal carcinoma in situ) pregnant women children
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Breast Cancer Female age 65 and older Staging: 1. Patients enrolled prior to surgery: Diagnosis of clinical T1-2N0 ER+ invasive breast cancer as determined by treating physician. DCIS or LCIS may be present with invasive cancer. 2. Patients enrolled after surgery: pT1-2NX, or pT1-2N0, ER+ invasive breast cancer. DCIS or LCIS may be present with invasive cancer Plan to undergo lumpectomy within 3 months of study registration, or underwent lumpectomy within 60 days of study registration (without sentinel node biopsy) Patients in whom lymph nodes are palpable and not suspicious who are found to be nodal tumor-free by nodal core needle biopsy are permitted, but those with biopsy-proven nodal metastases are excluded  Patients with diagnosis of ductal or lobular carcinoma in situ Patients with diagnosis of inflammatory breast cancer Patients who have undergone neoadjuvant chemotherapy for current primary breast cancer (past treatments for other cancers are acceptable) Patients planning to have mastectomy or had a mastectomy of the ipsilateral breast Prior history of ipsilateral (invasive or DCIS) breast cancer Diagnosis of clinical T3 or T4 breast cancer
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women years and older Histologically proven infiltrating carcinoma of the breast on diagnostic biopsy. NOTE: Individuals planning bilateral mastectomy procedures (for either bilateral cancers or contralateral prophylactic procedures) either at the same time or in the future will be asked to have tissue removed for the study from both breasts ER-negative, any PR status, and any HER2 status (i.e., ER-, PR any, HER2 or ER-, PR any, HER2+; "triple positive" breast cancers are not eligible) Unresected, untreated breast cancer planning surgical management with mastectomy (with or without axillary nodal evaluation/dissection and/or with any other clinical assessment) Willing and able to sign an informed consent form  None
Patient description: The patient is a 42 year-old postmenopausal woman who had a screening sonogram which revealed an abnormality in the right breast. She had no palpable masses on breast exam. Core biopsy was done and revealed a 1.8 cm infiltrating ductal breast carcinoma in the left upper outer quadrant. Lumpectomy was done and the surgical margins were clear. The tumor was HER2-positive and ER/PR negative. Axillary sampling revealed 1 positive lymph node out of 12 sampled. CXR was unremarkable. She is using “well women” multivitamins daily and no other medication. She smokes frequently and consumes alcohol occasionally. She is in a relation with only one partner and has a history of 3 pregnancies and live births. She breastfed all three children.

Clinical trial eligibility criteria: eligible ages (years): 55.0-999.0,  Carcinoma, Ductal, Breast Menopausal Non inflammatory unilateral and unifocal breast cancer with indication of lumpectomy Menopausal women with age > 55 years Tumor size <= 15 mm by ultrasonography Histological confirmation (by biopsy) of invasive ductal carcinoma with SBR (Scarff-Bloom-Richardson) grade (modified by Ellis & Elston) 1 or 2; hormone receptors positive (Estrogen Receptor and/or Progesterone Receptor) and negative Human epidermal growth factor receptor (HER2) Good lesion boundary with ultrasonography and MRI Minimal distance of 5 mm between the skin and the tumor Performance Status 0-1 Ability to understand and willingness to sign a written informed consent document Covered by a medical insurance Signed informed consent  Invasive lobular carcinoma Tumor with retro-nipple location Extended microcalcifications (> 15 mm) with mammography Xylocaine allergy Patient deprived of freedom